Pulmonary Arterial Hypertension Market By Drug Class (Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Activin Signaling Inhibitors / Novel Biologics); By Route of Administration (Oral Therapies, Intravenous (IV) / Subcutaneous (SC) Therapies, Inhalational Therapies); By Product Type (Branded Drugs, Generic Drugs); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

How Large Is the Global Pulmonary Arterial Hypertension Market, and What Are Its Key Clinical Applications and Treatment Opportunities? – (Updated On: 16th-Oct-2026)

The Global Pulmonary Arterial Hypertension Market was estimated at USD 9.18 billion in 2025 and is projected to reach USD 14.47 billion by 2032, expanding at a CAGR of 6.7% during 2026–2032, according to Strategic Market Research.

 

Pulmonary Arterial Hypertension (PAH) Market encompasses specialized pharmaceutical therapies, diagnostic technologies, and treatment services used to manage pulmonary arterial hypertension, a rare and progressive disease affecting the pulmonary arteries and right side of the heart.

 

PAH represents a substantial rare-disease treatment burden, with an estimated 191,808 patients living with the condition globally, 43,251 newly diagnosed cases, and 22,021 associated deaths, according to Global Burden of Disease 2021 estimates examined in research published in 2026. Women accounted for approximately 118,682 prevalent cases, representing 61.9% of the global PAH population. In the United States, the American Lung Association reported approximately 750 new PAH diagnoses annually, expressed as the midpoint of its published estimate. A 2026 analysis of U.S. mortality records identified 199 deaths coded to primary pulmonary hypertension in 2024, emphasizing the clinical importance of specialized diagnosis and long-term disease management.

 

The treatment landscape is increasingly shifting toward targeted pharmaceutical therapies and combination treatment strategies designed to improve pulmonary blood flow, reduce cardiac strain, and delay disease progression. Major therapeutic categories include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin pathway therapies, and activin signaling inhibitors. A U.S. insurance-claims study identified 2,712 treated PAH patients. The growing clinical adoption of advanced therapies such as sotatercept, supported by expanding regulatory approvals and favorable clinical outcomes, is strengthening treatment options for PAH patients and supporting the development of more personalized, disease-specific therapeutic strategies.

 

Overall, the Pulmonary Arterial Hypertension Market is progressing toward specialized, long-term pharmaceutical management, with treatment adoption, combination therapy utilization, and the introduction of clinically differentiated medicines shaping market revenue opportunities.

 

Which Subsegments Lead the Pulmonary Arterial Hypertension Market, and Where Are the Fastest-Expanding Opportunities?

By Drug Class: How Are Prostacyclin Therapies and Activin Inhibitors Shaping Treatment?

Leading Subsegment – Prostacyclin and Prostacyclin Analogs

Prostacyclin and prostacyclin analogs represent a major therapeutic category in the Pulmonary Arterial Hypertension Market, addressing impaired prostacyclin signaling to improve pulmonary vasodilation and reduce vascular resistance. The category accounted for an estimated 34.0% market share, equivalent to USD 3.121 billion in 2025, and is projected to expand at a CAGR of 5.70% during 2026–2032. Strong clinical utilization in advanced PAH, alongside expanding availability of oral, inhaled, and parenteral formulations, supports continued treatment adoption and long-term therapeutic expenditure.

Fastest-Growing Subsegment – Activin Signaling Inhibitors / Novel Biologics

Activin signaling inhibitors and novel biologics accounted for an estimated 18.0% of the global Pulmonary Arterial Hypertension Market, equivalent to USD 1.652 billion in 2025, and are projected to record the fastest CAGR of 13.00% during 2026–2032. The growing adoption of therapies such as sotatercept reflects a significant shift from conventional vasodilator treatments toward targeting abnormal vascular remodeling. Increasing clinical acceptance of activin signaling inhibition, supported by improved exercise capacity and reduced clinical worsening, is strengthening its position in advanced PAH treatment strategies.

 

By Route of Administration: How Do Oral Regimens and Injectable Therapies Shape Utilization?

Leading Subsegment – Oral Therapies

Oral therapies remain a cornerstone of the Pulmonary Arterial Hypertension Market, particularly in early- to intermediate-stage disease management, owing to their non-invasive administration, convenience, and suitability for long-term treatment. Oral therapies accounted for an estimated 53.0% market share, equivalent to USD 4.865 billion in 2025, and are projected to expand at a CAGR of 4.80% during 2026–2032. Their widespread use in combination treatment regimens, including endothelin receptor antagonists and phosphodiesterase-5 inhibitors, strengthens their position in ongoing pulmonary arterial hypertension management.

Fastest-Growing Subsegment – Intravenous (IV) / Subcutaneous (SC) Therapies

Intravenous and subcutaneous therapies represent a premium, life-saving treatment category, particularly for patients with advanced disease requiring continuous prostacyclin administration. Intravenous and subcutaneous therapies accounted for an estimated 32.0% market share, equivalent to USD 2.938 billion in 2025, and are projected to register the fastest CAGR of 9.40% during 2026–2032. Growing utilization of continuous infusion therapies, particularly epoprostenol and treprostinil, supports market expansion through specialized treatment programs and long-term therapy management.

 

By Product Type: Why Do Branded Drugs Lead Treatment Expenditure?

Leading and Fastest-Growing Subsegment – Branded Drugs

Branded drugs maintained their dominant position in the Global Pulmonary Arterial Hypertension Market, accounting for an estimated 80.0% market share, equivalent to USD 7.344 billion in 2025, and are projected to register the fastest CAGR of 7.50% during 2026–2032. Their leadership reflects the widespread adoption of innovative PAH therapies, including targeted combination treatments and advanced formulations. Continued investment in clinical innovation, improved treatment outcomes, and physician preference for established branded therapies further strengthens their market position despite increasing competition from generic alternatives.

 

By Geography: How Do Specialty Care Networks Influence Regional Adoption?

Leading Regional Subsegment – North America

North America accounted for an estimated 44.0% share of the global Pulmonary Arterial Hypertension Market, equivalent to USD 4.039 billion in 2025, and is projected to expand at a CAGR of 5.65% during 2026–2032. Regional growth is supported by increasing adoption of targeted PAH therapies, advanced right-heart catheterization diagnostics, and specialized pulmonary hypertension treatment centers. The United States remains the leading contributor, supported by FDA-approved therapies, including sotatercept, improved disease recognition, established specialty care networks, and broader access to combination treatment regimens.

Fastest-Growing Regional Subsegment – Asia-Pacific

Asia-Pacific accounted for an estimated 19.0% share of the global Pulmonary Arterial Hypertension Market, equivalent to USD 1.744 billion in 2025, and is projected to register the fastest regional CAGR of 9.00% during 2026–2032. Regional expansion reflects increasing adoption of PAH-specific diagnostic protocols, specialized pulmonary hypertension centers, and advanced therapies, including endothelin receptor antagonists and prostacyclin pathway treatments. Improving access to specialist care across China, Japan, and India supports treatment uptake, although healthcare infrastructure, affordability, and geographic disparities continue to influence market penetration.

 

How Are New Treatment Options Transforming the Pulmonary Arterial Hypertension Market?

Novel Biologic Therapies: Sotatercept (Winrevair)

Merck's Winrevair (sotatercept-csrk) represents a major advancement in PAH treatment through its novel activin signaling inhibition technology. Unlike conventional vasodilators that primarily relax pulmonary blood vessels, sotatercept targets signaling pathways involved in abnormal vascular cell proliferation. Administered through a subcutaneous injection once every three weeks, it is designed to complement existing PAH therapies.

In the pivotal STELLAR trial involving 323 patients, sotatercept demonstrated an approximately 41-meter improvement in six-minute walking distance compared with placebo at 24 weeks. Additional evidence from the ZENITH trial strengthened its clinical position in patients with advanced disease. The updated European Respiratory Society guidelines recommend add-on sotatercept for appropriately selected patients at intermediate or high risk. These developments create significant opportunities for branded biologics and combination treatment expenditure, while requiring specialist monitoring for bleeding, platelet abnormalities, and elevated hemoglobin.

Fixed-Dose Oral Combination Therapy: Opsynvi

Johnson & Johnson's Opsynvi combines macitentan, an endothelin receptor antagonist, and tadalafil, a PDE-5 inhibitor, into a single once-daily oral tablet. The treatment simultaneously targets two established PAH pathways, supporting pulmonary vasodilation and reducing vascular resistance.

The Phase III A DUE trial demonstrated that the fixed-dose combination improved pulmonary vascular resistance compared with either macitentan or tadalafil alone. By combining two active medicines into one tablet, Opsynvi reduces treatment complexity and supports more convenient long-term disease management. Its adoption aligns with recommendations favoring initial combination therapy for eligible patients, strengthening opportunities in the branded oral PAH treatment category.

Investigational Inhaled Therapy: Seralutinib

Seralutinib, developed through the Gossamer Bio–Chiesi collaboration, is an investigational inhaled tyrosine kinase inhibitor targeting pathways associated with pulmonary vascular proliferation, inflammation, and fibrosis. Its inhaled administration offers a potential approach to delivering treatment directly to the lungs while complementing existing PAH medications.

The Phase III PROSERA trial enrolled 390 patients and reported a 13.3-meter placebo-adjusted improvement in six-minute walking distance at 24 weeks. However, the study did not meet its prespecified primary statistical significance threshold. A predefined intermediate- and high-risk subgroup showed a 20.0-meter improvement, providing a potential direction for further research. Seralutinib therefore remains a development opportunity rather than an established approved treatment.

Risk-Based Combination Therapy and Advanced Disease Management

PAH treatment is increasingly moving toward early combination therapy and individualized treatment escalation. For appropriate newly diagnosed patients, combining an endothelin receptor antagonist with a PDE-5 inhibitor provides a broader therapeutic approach than conventional single-drug initiation.

Patients with advanced or high-risk disease may require intravenous epoprostenol, subcutaneous or intravenous treprostinil, and additional targeted medications. The availability of sotatercept has expanded the potential for four-pathway treatment regimens in selected patients. This strategy increases the importance of specialist pulmonary hypertension centers, ongoing risk assessment, and sustained pharmaceutical treatment

 

Which Companies Are Leading the Pulmonary Arterial Hypertension Market, and How Are They Strengthening Their Competitive Positions?

Johnson & Johnson (Actelion Pharmaceuticals) — Leader in Oral Combination and Prostacyclin-Pathway Therapies

Johnson & Johnson maintains a significant position through Opsumit (macitentan), Opsynvi (macitentan/tadalafil), and Uptravi (selexipag), addressing multiple established PAH treatment pathways. According to its 2025 financial results, the company's pulmonary hypertension portfolio generated USD 4.437 billion in worldwide sales, increasing 3.6% from USD 4.282 billion in 2024. Opsumit/Opsynvi contributed USD 2.325 billion, while Uptravi generated USD 1.902 billion. Its established specialty treatment portfolio and fixed-dose combination strategy strengthen its position in long-term PAH management.

United Therapeutics Corporation — Leader in Prostacyclin and Inhaled PAH Therapies

United Therapeutics specializes in prostacyclin-based treatment through Tyvaso, Tyvaso DPI, Remodulin, and Orenitram, providing inhaled, oral, and continuous infusion treatment options. Its Tyvaso franchise generated USD 1.878 billion in 2025 sales, increasing 16% from USD 1.620 billion in 2024. The expansion of dry-powder inhaled treprostinil reflects the importance of convenient pulmonary drug delivery. Its diversified administration technologies support treatment across different disease stages and reinforce its competitive position in prostacyclin therapies.

Merck & Co., Inc. — Leader in Novel Biologic PAH Treatment

Merck has emerged as a major innovator through Winrevair (sotatercept), an activin signaling inhibitor targeting disease-related vascular pathways beyond conventional vasodilation. Merck reported USD 1.443 billion in Winrevair sales in 2025, compared with USD 419 million in 2024, representing substantial adoption following its introduction. Clinical evidence showing improvements in exercise capacity and reduced clinical worsening supports its use alongside established therapies. Winrevair's expansion strengthens Merck's position in the higher-value biologic treatment category.

Other Key Companies and Their Roles in the Pulmonary Arterial Hypertension Market

• Bayer AG — Markets Adempas (riociguat), a soluble guanylate cyclase stimulator approved for PAH, providing an alternative targeted treatment pathway.

• Liquidia Corporation — Markets Yutrepia, an inhaled dry-powder treprostinil treatment for PAH, expanding competition in pulmonary drug-delivery therapies.

• Gilead Sciences, Inc. — Has participated in the PAH market through Letairis (ambrisentan), an endothelin receptor antagonist used in oral treatment regimens.

• Pfizer Inc. — Established a presence through Revatio (sildenafil), a PDE-5 inhibitor used in PAH treatment, with generic competition influencing the established therapy category.

• GSK plc — Has a historical role in advanced PAH treatment through Flolan (epoprostenol), a continuous intravenous prostacyclin therapy.

• Bristol Myers Squibb — Participates financially in sotatercept through licensing and royalty arrangements, while Merck retains worldwide PAH commercialization rights.

• MannKind Corporation — Provides Technosphere dry-powder technology and manufacturing capabilities for Tyvaso DPI through its collaboration with United Therapeutics.

 

Analyst Commentary: How Will Disease-Modifying Therapies and Earlier Intervention Shape PAH Treatment?

The Pulmonary Arterial Hypertension Market is shifting toward disease-modifying biologics, early combination therapy, and personalized risk-based treatment. Key opportunities lie in activin signaling inhibitors, targeted injectable therapies, and advanced inhaled formulations. Greater emphasis on early diagnosis, treatment escalation, and improving long-term clinical outcomes is expected to increase adoption of innovative therapies and expand treatment opportunities for high-risk PAH patients.

 

Pulmonary Arterial Hypertension Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 9.18 Billion
Revenue Forecast in 2032	USD 14.47 Billion
Overall Growth Rate	CAGR of 6.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Drug Class, By Route of Administration, By Product Type, By Geography
By Drug Class	Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Activin Signaling Inhibitors / Novel Biologics
By Route of Administration	Oral Therapies, Intravenous (IV) / Subcutaneous (SC) Therapies, Inhalational Therapies
By Product Type	Branded Drugs, Generic Drugs
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Growing global burden of pulmonary arterial hypertension, increasing adoption of targeted PAH therapies, rising use of combination treatment strategies, expansion of activin signaling inhibitors and novel biologics, growing adoption of sotatercept, increasing use of prostacyclin pathway therapies, demand for oral and inhaled treatment options, expansion of specialized pulmonary hypertension centers, improved access to advanced PAH diagnostics and therapies, and increasing emphasis on individualized risk-based treatment
Customization Option	Available upon request